Retatrutide 60MG

Product details

Retatrutide

INN: Retatrutide
CAS Number: 2381089-83-2
Molecular Formula: C309H486F3N91O98
Molecular Weight: ~7264.15 g/mol
Synonyms: LY3437943, Triple G Agonist
Drug Class: Dual or triple incretin receptor agonist (GIP, GLP-1, and glucagon receptor agonist)
Form: White or off-white lyophilized powder
Purity: ≥98% (HPLC)
Solubility: Soluble in sterile water and aqueous buffers (e.g., PBS)
Storage: Store lyophilized at –20°C; after reconstitution, refrigerate at 2–8°C
Shelf Life: 24 months (lyophilized, unopened)

🔬 Product Overview:

Retatrutide is a novel multi-receptor agonist peptide developed to target three key metabolic hormone receptors:

Glucose-dependent insulinotropic polypeptide (GIP) receptor

Glucagon-like peptide-1 (GLP-1) receptor

Glucagon receptor (GCGR)

This triple agonist design represents a cutting-edge therapeutic strategy for addressing metabolic disorders such as obesity, type 2 diabetes (T2DM), and potentially non-alcoholic steatohepatitis (NASH). Retatrutide is currently in advanced clinical trials and has demonstrated unprecedented levels of weight reduction and glycemic control in early studies.

✅ Key Features & Research Highlights:

Triple receptor activation: GIP + GLP-1 + Glucagon

Potent weight loss effects, exceeding those of GLP-1 agonists alone

Improves insulin sensitivity and fasting/postprandial glucose levels

Increases energy expenditure via glucagon receptor stimulation

Reduces appetite and caloric intake through central satiety mechanisms

Shown to improve lipid metabolism and hepatic fat content in studies

Long-acting structure allows weekly subcutaneous administration

⚙️ Mechanism of Action:

Retatrutide exerts metabolic benefits through synergistic activation of:

GIP receptor – Enhances insulin secretion and may improve adipose metabolism

GLP-1 receptor – Suppresses appetite, slows gastric emptying, improves beta-cell function

Glucagon receptor – Promotes energy expenditure and lipid oxidation, aiding fat loss

This multi-agonist approach allows Retatrutide to act both centrally and peripherally, delivering superior weight loss and glucose control than single-pathway agents.